3D-printed patch treats smaller ischemic blood vessels

Surgery is one way of treating ischemia, but it becomes exponentially more complicated the smaller the vessels are. Developing a new treatment for the smallest vessels, researchers have started work on 3D printed patches capable of infusing with cells to grow healthy blood vessels. Research is published in the latest issue of Nature Biomedical Engineering.

Led by professor Christopher Chen, MSE, researchers paired with Innolign, a biomedical technology company in Boston, to develop a patch to activate growth of new vessels without the complications of surgery. 3D printing the patches on a small scale of 100 microns allowed researchers to change and test their designs to find the right fit.

"Therapeutic angiogenesis, when growth factors are injected to encourage new vessels to grow, is a promising experimental method to treat ischemia," said Chen. "One of the questions we were trying to answer is whether or not architecture of the implant mattered, and this showed us that yes, it does, which is why our unique approach using a 3D printer was important. The pre-organized architecture of the patch helped to guide the formation of new blood vessels that seemed to deliver sufficient blood to the downstream tissue. While it wasn't a full recovery, we observed functional recovery of function in the ischemic tissue."

The research team develop two patches using endothelial cells, one with pre-organized structures and the second with the cells injected without any structure. Testing the patches showed pre-organization of structures allowed for a reduction of ischemia.

"This project has been long in the making, and our clinical collaborators have been indispensable to the success of the project," Chen said. "As a bioengineer, we were focused on how to actually build the patch itself, while the clinical perspective was critical to the design process. We look forward to continuing our partnerships as we move forward."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup